For example, the frequency of HER2-low disease is higher in HR-positive breast cancer than TNBC (65.4% vs. 36.6%) and most HER2-low tumors are HR-positive (88.2%) or Luminal A or B (79.6%). This evidence concerns the gene ERBB2 and breast carcinoma.